The study of abnormal bone development in the Apert syndrome Fgfr2+/S252W mouse using a 3D hydrogel culture model

Bone

Volumn 43, Issue 1, 2008, Pages 55-63

  Yang, Fan ^a   Wang, Yingli ^b   Zhang, Zijun ^c   Hsu, Bryan ^c   Jabs, Ethylin Wang ^b   Elisseeff, Jennifer H ^c  

^a USA   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Johns Hopkins University School of Medicine   (United States)

Author keywords

Apert syndrome; FGFR2; Hydrogel; Osteoblast; Tissue engineering

Indexed keywords

ALIZARIN RED S; COLLAGEN TYPE 1; COLLAGEN TYPE 11; FIBROBLAST GROWTH FACTOR RECEPTOR 2; METALLOPROTEINASE; NOGGIN; OSTEOCALCIN;

ACROCEPHALOSYNDACTYLY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE MINERALIZATION; BONE REMODELING; CELL ENCAPSULATION; CELL FUNCTION; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; GENE MUTATION; HYDROGEL; IMMUNOFLUORESCENCE; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; LIMB; MONOLAYER CULTURE; MOUSE; NONHUMAN; OSTEOBLAST; PATHOGENESIS; PERINATAL PERIOD; PHENOTYPE; PROTEIN BINDING; STAINING; STATISTICAL SIGNIFICANCE; TISSUE ENGINEERING; WILD TYPE;

ACROCEPHALOSYNDACTYLIA; ALKALINE PHOSPHATASE; ANIMALS; BASE SEQUENCE; BONE AND BONES; BONE DEVELOPMENT; CALCIFICATION, PHYSIOLOGIC; CELL CULTURE TECHNIQUES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DNA PRIMERS; HYDROGELS; IN SITU HYBRIDIZATION; LIGANDS; MICE; MUTATION; OSTEOPONTIN; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 44949111335     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.02.008     Document Type: Article

References (38)

1. Chen L., and Deng C.X. Roles of FGF signaling in skeletal development and human genetic diseases. Front Biosci 10 (2005) 1961-1976
2. Ornitz D.M., and Marie P.J. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 16 (2002) 1446-1465
3. Cohen Jr. M.M., Kreiborg S., Lammer E.J., Cordero J.F., Mastroiacovo P., Erickson J.D., Roeper P., and Martinez-Frias M.L. Birth prevalence study of the Apert syndrome. Am J Med Genet 42 (1992) 655-659
4. Cohen Jr. M.M., and Kreiborg S. New indirect method for estimating the birth prevalence of the Apert syndrome. Int J Oral Maxillofac Surg 21 (1992) 107-109
5. Wilkie A.O., Slaney S.F., Oldridge M., Poole M.D., Ashworth G.J., Hockley A.D., Hayward R.D., David D.J., Pulleyn L.J., and Rutland P. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat Genet 9 (1995) 165-172
6. Park W.J., Theda C., Maestri N.E., Meyers G.A., Fryburg J.S., Dufresne C., Cohen Jr. M.M., and Jabs E.W. Analysis of phenotypic features and FGFR2 mutations in Apert syndrome. Am J Hum Genet 57 (1995) 321-328
7. Anderson J., Burns H.D., Enriquez-Harris P., Wilkie A.O., and Heath J.K. Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. Hum Mol Genet 7 (1998) 1475-1483
8. Yu K., Herr A.B., Waksman G., and Ornitz D.M. Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. Proc Natl Acad Sci U S A 97 (2000) 14536-14541
9. Ibrahimi O.A., Zhang F., Eliseenkova A.V., Itoh N., Linhardt R.J., and Mohammadi M. Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum Mol Genet 13 (2004) 2313-2324
10. Arman E., Haffner-Krausz R., Chen Y., Heath J.K., and Lonai P. Targeted disruption of fibroblast growth factor (FGF) receptor 2 suggests a role for FGF signaling in pregastrulation mammalian development. Proc Natl Acad Sci U S A 95 (1998) 5082-5087
11. Wang Y., Xiao R., Yang F., Karim B.O., Iacovelli A.J., Cai J., Lerner C.P., Richtsmeier J.T., Leszl J.M., Hill C.A., Yu K., Ornitz D.M., Elisseeff J., Huso D.L., and Jabs E.W. Abnormalities in cartilage and bone development in the apert syndrome FGFR2(+/S252W) mouse. Development 132 (2005) 3537-3548
12. Chen L., Li D., Li C., Engel A., and Deng C.X. A Ser252Trp substitution in mouse fibroblast growth factor receptor 2 (Fgfr2) results in craniosynostosis. Bone 33 (2003) 169-178
13. Mansukhani A., Bellosta P., Sahni M., and Basilico C. Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J Cell Biol 149 (2000) 1297-1308
14. De Pollack C., Renier D., Hott M., and Marie P.J. Increased bone formation and osteoblastic cell phenotype in premature cranial suture ossification (craniosynostosis). J Bone Miner Res 11 (1996) 401-407
15. Chun T.H., Hotary K.B., Sabeh F., Saltiel A.R., Allen E.D., and Weiss S.J. A pericellular collagenase directs the 3-dimensional development of white adipose tissue. Cell 125 (2006) 577-591
16. Cukierman E., Pankov R., Stevens D.R., and Yamada K.M. Taking cell-matrix adhesions to the third dimension. Science 294 (2001) 1708-1712
17. Bissell M.J., and Radisky D. Putting tumours in context. Nat Rev Cancer 1 (2001) 46-54
18. Walpita D., and Hay E. Studying actin-dependent processes in tissue culture. Nat Rev Mol Cell Biol 3 (2002) 137-141
19. Grinnell F. Fibroblast biology in three-dimensional collagen matrices. Trends Cell Biol 13 (2003) 264-269
20. Yamada K.M. Cell biology: tumour jailbreak. Nature 424 (2003) 889-890
21. Boudreau N., and Weaver V. Forcing the third dimension. Cell 125 (2006) 429-431
22. Hotary K.B., Allen E.D., Brooks P.C., Datta N.S., Long M.W., and Weiss S.J. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 114 (2003) 33-45
23. Elisseeff J., Anseth K., Sims D., McIntosh W., Randolph M., and Langer R. Transdermal photopolymerization for minimally invasive implantation. Proc Natl Acad Sci U S A 96 (1999) 3104-3107
24. Yang F., Williams C.G., Wang D.A., Lee H., Manson P.N., and Elisseeff J. The effect of incorporating RGD adhesive peptide in polyethylene glycol diacrylate hydrogel on osteogenesis of bone marrow stromal cells. Biomaterials 26 (2005) 5991-5998
25. Williams C.G., Kim T.K., Taboas A., Malik A., Manson P., and Elisseeff J. In vitro chondrogenesis of bone marrow-derived mesenchymal stem cells in a photopolymerizing hydrogel. Tissue Eng 9 (2003) 679-688
26. McLeod M.J. Differential staining of cartilage and bone in whole mouse fetuses by alcian blue and alizarin red S. Teratology 22 (1980) 299-301
27. Wilkinson D.G. In situ hybridization: a practical approach (1992), Oxford University Press, London, UK
28. Shin H., Zygourakis K., Farach-Carson M.C., Yaszemski M.J., and Mikos A.G. Modulation of differentiation and mineralization of marrow stromal cells cultured on biomimetic hydrogels modified with Arg-Gly-Asp containing peptides. J Biomed Mater Res A 69 (2004) 535-543
29. Trojani C., Weiss P., Michiels J.F., Vinatier C., Guicheux J., Daculsi G., Gaudray P., Carle G.F., and Rochet N. Three-dimensional culture and differentiation of human osteogenic cells in an injectable hydroxypropylmethylcellulose hydrogel. Biomaterials 26 (2005) 5509-5517
30. Benoit D.S., Durney A.R., and Anseth K.S. Manipulation in hydrogel degradation behavior enhance osteoblasts function and mineralized tissue formation. Tissue Eng 12 (2006) 1663-1673
31. Chung E.H., Gilbert M., Virdi A.S., Sena K., Sumner D.R., and Healy K.E. Biomimetic artificial ECMs stimulate bone regeneration. J Biomed Mater Res A 79 (2006) 815-826
32. Sharma B., and Elisseeff J.H. Engineering structurally organized cartilage and bone tissues. Ann Biomed Eng 32 1 (2004) 148-159
33. Owen T.A., Aronow M., Shalhoub V., Barone L.M., Wilming L., Tassinari M.S., Kennedy M.B., Pockwinse S., Lian J.B., and Stein G.S. Progressive development of the rat osteoblast phenotype in vitro: reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix. J Cell Physiol 143 (1990) 420-430
34. Plotnikov A.N., Hubbard S.R., Schlessinger J., and Mohammadi M. Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell 101 (2000) 413-424
35. Baroni T., Carinci P., Lilli C., Bellucci C., Aisa M.C., Scapoli L., Volinia S., Carinci F., Pezzetti F., Calvitti M., Farina A., Conte C., and Bodo M. P253R fibroblast growth factor receptor-2 mutation induces RUNX2 transcript variants and calvarial osteoblast differentiation. J Cell Physiol 202 (2005) 524-535
36. Warren S.M., Brunet L.J., Harland R.M., Economides A.N., and Longaker M.T. The BMP antagonist noggin regulates cranial suture fusion. Nature 422 (2003) 625-629
37. Holten I.W., Smith A.W., Bourne A.J., and David D.J. The Apert syndrome hand: pathologic anatomy and clinical manifestations. Plast Reconstr Surg 99 (1997) 1681-1687
38. Tanimoto Y., Yokozeki M., Hiura K., Matsumoto K., Nakanishi H., Matsumoto T., Marie P.J., and Moriyama K. A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome. J Biol Chem 279 44 (2004) 45926-45934